Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601198 · ClinicalTrials.gov registry record · Phase 2
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
A Phase 2 study, sponsored by University of Cincinnati.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00601198: Clinical Trial Phase 2 study, sponsored by University of Cincinnati.
NCT00601198 is a Phase 2 study that was terminated before completion, run by University of Cincinnati. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00601198, a Phase 2 study, was terminated before completion, sponsored by University of Cincinnati.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of amifostine (ETHYOL) on decreasing the rate and severity of nerve dysfunction or neuropathy (numbness and tingling in hands and feet) associated with FOLFOX chemotherapy.
Primary Outcome
There were only four participants in this study. None of which completed the questionnaires needed to assess this outcome. This study was closed by the sponsor on January 13, 2010 due to low enrollment.
Interventions
- DRUG Amifostine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-01-13 |
| Phase | Phase 2 |
Why NCT00601198 stopped before completion
NCT00601198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Amifostine is the first listed.
NCT00601198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00601198 about?
NCT00601198 is a clinical study titled "A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer". The purpose of this study is to determine the effect of amifostine (ETHYOL) on decreasing the rate and severity of nerve dysfunction or neuropathy (numbness and tingling in hands and feet) associated with FOLFOX chemotherapy.
What is the current status of trial NCT00601198?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2006-10. Estimated completion is 2010-01-13.
What interventions are being tested in trial NCT00601198?
The interventions under investigation include: Amifostine (DRUG).
Who is sponsoring clinical trial NCT00601198?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00601198's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia